OncoMatch/Clinical Trials/NCT07408635
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Is NCT07408635 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies IBI363 + Chemotherapy for unresectable stage iii non-small cell lung cancer.
Treatment: IBI363 + Chemotherapy — This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR active mutation
Non-squamous and squamous NSCLC with EGFR active mutation positive ... are excluded
Required: ALK rearrangement
Non-squamous and squamous NSCLC with ... ALK rearrangement ... are excluded
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Lab requirements
Blood counts
anc count ≥ 1.5 × 10⁹/l; platelet count ≥ 100 × 10⁹/l; hemoglobin ≥ 90 g/l
Kidney function
serum cr ≤ 1.5 times of upper limit of normal (uln) or calculated creatinine clearance (clcr) ≥ 50 ml/min
Liver function
total bilirubin ≤ 1.5 × uln (≤ 3 × uln in gilbert's syndrome); ast and alt ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50 %
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify